Previous 10 | Next 10 |
Strongbridge Biopharma, Inc (SBBP) Q3 2018 Earnings Conference Call October 31, 2018 09:15 AM ET Executives Lindsay Rocco - Elixir Health Public Relations Matthew Pauls - President and CEO Dr. Fred Cohen - Chief Medical Officer Brian Davis - Chief Financial Officer Analysts ...
Veeco Instruments (NASDAQ: VECO ) -32% on Q3 earnings . More news on: Veeco Instruments Inc., Ballard Power Systems, Inc., Encana Corporation, Stocks on the move, , Top stock market news, Read more ...
November 1, 2018 Palm Beach, FL – (November 1, 2018) – Multiple myeloma (MM) known as a plasma cell malignancy that affects 14,000 patients per year are fueling the development and clinical activities for new therapies to treat these malignancies. Recent clinical trial resu...
NEW YORK, NY / ACCESSWIRE / November 1, 2018 / Strongbridge Biopharma was one of the biggest winners in the biotech arena yesterday after announcing a deal with Denmark’s Novo Nordisk. Shares of Clovis Oncology were in the red after reporting third quarter results. RDI Initiates Cov...
More news on: Strongbridge Biopharma, AEterna Zentaris, Inc., Accuray Incorporated, Stocks on the move, , Read more ...
Thinly traded nano cap Aeterna Zentaris ( AEZS +58.5% ) is up on a whopping 159x surge in volume in reaction to Strongbridge Biopharma's ( SBBP +39.5% ) out-licensing deal with Novo Nordisk for U.S. and Canadian rights to MACRILEN (macimorelin). More news on: AEterna Zentaris, Inc., St...
Strongbridge Biopharma ( SBBP +33.1% ) is up on more than triple normal volume in early trade in response to its out-licensing deal with Novo Nordisk ( NVO +1.8% ) for U.S. and Canadian rights to MACRILEN (macimorelin), used in the diagnosis of adult growth hormone deficiency. ...
Strongbridge Biopharma (NASDAQ: SBBP ): Q3 GAAP EPS of -$0.55 misses by $0.16 . More news on: Strongbridge Biopharma, Earnings news and commentary, Healthcare stocks news, , Read more ...
~ Financial Position to be Significantly Strengthened in Fourth Quarter 2018 by $145 Million of Upfront Cash and $36.7 Million Equity Investment from Separately Announced Transactions with Novo Nordisk; Company Intends to Utilize Portion of Proceeds to Repay Outstanding Debt of $88 Million...
~ Strongbridge to Receive Upfront Payment of $145 Million and Tiered Royalty Stream from Novo Nordisk ~ ~ Novo Nordisk to Purchase Approximately 5.2 Million Ordinary Shares of Strongbridge Biopharma plc at Purchase Price of $7.00 per Share, Resulting in Gross Proceeds of $36.7 Million...
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...